New generation azole antifungals in clinical investigation

Expert Opinion on Investigational Drugs

Volumn 18, Issue 9, 2009, Pages 1279-1295

  Girmenia, Corrado ^a  

^a POLICLINICO UMBERTO I   (Italy)

Author keywords

Albaconazole; Isavuconazole; Posaconazole; Ravuconazole; Triazoles; Voriconazole

Indexed keywords

4 [2 [2 (2,5 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 THIAZOLYL]BENZONITRILE; ALBACONAZOLE; ALFENTANIL; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; ASTEMIZOLE; BENZODIAZEPINE DERIVATIVE; BMS 379224; CALCIUM CHANNEL BLOCKING AGENT; CASPOFUNGIN; CISAPRIDE; COUMARIN; CYCLODEXTRIN; CYCLOSPORIN; EFAVIRENZ; ERGOT ALKALOID; FLUCONAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISAVUCONAZOLE; ISAVUCONAZONIUM; ITRACONAZOLE; OMEPRAZOLE; PHENYTOIN; POSACONAZOLE; PRODRUG; RAVUCONAZOLE; RAVUCONAZOLE DILYSINE PHOSPHOESTER; RIFAMPICIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ABNORMAL VISION; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDEMIA; CANDIDIASIS; CHROMOMYCOSIS; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; COLOR VISION; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG STRUCTURE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; ERYTHEMA MULTIFORME; ESOPHAGUS CANDIDIASIS; FOOD; FOOD DRUG INTERACTION; FUSARIOSIS; GENETIC POLYMORPHISM; HALLUCINATION; HEART ARREST; HEART VENTRICLE ARRHYTHMIA; HEPATITIS; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; JAUNDICE; KIDNEY DYSFUNCTION; LIVER CELL DAMAGE; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FUNCTION TEST; LUNG ASPERGILLOSIS; MINIMUM INHIBITORY CONCENTRATION; MOULD; MYCETOMA; MYCOSIS; NAUSEA; NONHUMAN; ONYCHOMYCOSIS; OROPHARYNX CANDIDIASIS; PHOTOPHOBIA; PLASMA PROTEIN BINDING; QT PROLONGATION; REVIEW; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SUDDEN DEATH; TACHYCARDIA; THROMBOCYTOPENIA; TORSADE DES POINTES; TOXIC EPIDERMAL NECROLYSIS; VAGINA CANDIDIASIS; VITAL SIGN; VOMITING; VULVOVAGINITIS;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLUS; AZOLES; CANDIDA; CLINICAL TRIALS AS TOPIC; CRYPTOCOCCUS NEOFORMANS; DRUG DESIGN; DRUG INTERACTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES;

EID: 68849117064     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903176407     Document Type: Review

References (100)

1. Charlier C, Hart E, Lefort A, et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006;57:384-410
2. Maertens J, Boogaerts M. The place for itraconazole in treatment. J Antimicrob Chemother 2005;56(Suppl 1):i33-8
3. Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J Antimicrob Chemother 2008;61(Suppl 1):i19-30
4. Bellmann R. Clinical pharmacokinetics of systemically administered antimycotics. Curr Clin Pharmacol 2007;2:37-58
5. Zonios DI, Bennett JE. Update on azole antifungals. Semin Respir Crit Care Med 2008;29:198-210
6. Schmitt-Hoffmann A, Roos B, Heep M, et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006;50:279-85
7. Schmitt-Hoffmann A, Roos B, Maares J, et al Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006;50:286-93
8. Odds FC. Drug evaluation: BAL-8557 - a novel broad-spectrum triazole antifungal. Curr Opin Investig Drugs 2006;7:766-72
9. Guinea J, Bouza E. Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections. Future Microbiol 2008;3:603-15
10. Olsen SJ, Mummaneni V, Rolan P, et al. Ravuconazole single ascending oral dose study in healthy subjects. In: abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000. Abstract A-838. American Society for Microbiology, Washington, DC, USA
11. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003;47:1193-9
12. Petraitiene R, Petraitis V, Lyman CA, et al. Antimicrob Agents Chemother 2004;48:1188-96
13. Groll AH, Mickiene D, Petraitis V, et al Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits. J Antimicrob Chemother 2005;56:899-907
14. Gupta AK, Leonardi C, Stoltz RR, et al. A phase I/II randomized,double- blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J Eur Acad Dermatol Venereol 2005;19:437-43
15. Lin P, Mickiene D, Roden MM, et al. Pharmacokinetics and safety of ravuconazole for prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation. In: abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract A-220. American Society for Microbiology, Washington, DC, USA
16. Izquierdo I, Lurigados C, Perez I, et al. First administration into man of UR-9825: a new triazole class of antifungal agent. In: abstracts of the Sixth Congress of the European Confederation of Medical Mycology Societies (ECMM), Barcelona, Spain, 2000:P2-004
17. Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004;48:804-8
18. Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004;57:218-22
19. Krishna G, Moton A, Ma L, et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009;53:958-66
20. Krishna G, Abu Tarif M, Xuan F, et al. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 2008;28:1223-32
21. Krishna G, Martinho M, Chandrasekar P, et al. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007;27:1627-36
22. Schmitt-Hoffmann A, Roos B, Spickermann J, et al. No relevant food effect in man on isavuconazole oral pharmacokinetics preliminary data. In: abstracts of the Forty-eight Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2008. Abstract A-008. American Society for Microbiology, Washington, DC, USA
23. Scott LJ, Simpson D. Voriconazole : a review of its use in the management of invasive fungal infections. Drugs 2007;67:269-98
24. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006;45:649-63
25. Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH. Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother 2008;42:1429-38
26. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009;53:24-34
27. Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007;45:1610-7
28. Torres HA, Hachem RY, Chemaly RF, et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005;5:775-85
29. Potoski BA, Brown J. The safety of voriconazole. Clin Infect Dis 2002;35:1273-5
30. Schmitt-Hiffmann A, Roos Bm Spickermann J, Heep M, et al. Pharmacokinetics of isavuconazole in liver impairment preliminary data. In: abstracts of the Forty-eight Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2008. Abstract A-007. American Society for Microbiology, Washington, DC, USA
31. Espinel-Ingroff A. Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi. Rev Iberoam Micol 2008;25:101-6
32. Rogers TR. Antifungal drug resistance: limited data, dramatic impact? Int J Antimicrob Agents 2006;27(Suppl 1):7-11
33. Mann PA, Parmegiani RM, Wei SQ, et al. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14 -demethylase. Antimicrob Agents Chemother 2003;47:577-81
34. Nascimento AM, Goldman GH, Park S, et al. Antimicrob Agents Chemother 2003;47:1719-26
35. Chamilos G, Kontoyiannis DP. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Drug Resist Updat 2005;8:344-58
36. Werweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007;356:1481-3
37. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007;51:1897-904
38. Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, et al. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 2008;52:2468-72
39. Garcia-Effron G, Dilger A, Alcazar-Fuoli L, et al. Rapid detection of triazole antifungal resistance in Aspergillus fumigatus. J Clin Microbiol 2008;46(4):1200-6
40. Lass-Flörl C, Mayr A, Perkhofer S, et al. assessment according to the methodology of the European Committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother 2008;52:3637-41
41. Pfaller MA, Messer SA, Boyken L, et al. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J Clin Microbiol 2008;46:551-9
42. Seifert H, Aurbach U, Stefanik D, Cornely O. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob Agents Chemother 2007;51:1818-21
43. Illnait-Zaragozi MT, Martínez GF, Curfs-Breuker I, et al. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother 2008;52:1580-2
44. Guinea J, Peláez T, Recio S, et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008;52:1396-400
45. Messer SA, Jones RN, Fritsche TR. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). J Clin Microbiol 2006;44:1782-7
46. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates. Antimicrob Agents Chemother 2004;48:3107-11
47. Pfaller MA, Messer SA, Boyken L, et al. Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J Clin Microbiol 2004;42:3137-41
48. Pfaller MA, Diekema DJ, Messer SA, et al. In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. Diagn Microbiol Infect Dis 2004;48:101-5
49. Pfaller MA, Messer SA, Hollis RJ, et al. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002;46:1723-7
50. Pfaller MA, Messer SA, Boyken L, et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005;43:2163-7
51. Pfaller MA, Diekema DJ, Jones RN, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001;39:3254-9
52. Yamazumi T, Pfaller MA, Messer SA, et al. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 2000;44:2883-6
53. Diekema DJ, Pfaller MA, Messer SA, et al. In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY antimicrobial surveillance program in North America and Latin America. Antimicrob Agents Chemother 1999;43:2236-9
54. Miller JL, Schell WA, Wills EA, et al. In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob Agents Chemother 2004;48:384-7
55. Ramos G, Cuenca-Estrella M, Monzón A, Rodríguez-Tudela JL. In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp. J Antimicrob Chemother 1999;44:283-6
56. Fung-Tomc JC, White TC, Minassian B, et al. In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole. Diagn Microbiol Infect Dis 1999;35:163-7
57. Girmenia C, Pizzarelli G, D'Antonio D, et al. In vitro susceptibility testing of Geotrichum capitatum: comparison of the E-test, disk diffusion, and Sensititre colorimetric methods with the NCCLS M27-A2 broth microdilution reference method. Antimicrob Agents Chemother 2003;47:3985-8
58. Taj-Aldeen SJ, Al-Ansari N, El Shafei S, et al. Isolation of Trichosporon dohaense Taj-Aldeen, Meis & Boekhout sp. nov. J Clin Microbiol 2009;47:1791-9
59. Espinel-Ingroff A, Arthington-Skaggs B, Iqbal N, et al. J Clin Microbiol 2007;45:1811-20
60. Espinel-Ingroff A, Johnson E, Hockey H, Troke P. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. J Antimicrob Chemother 2008;61:616-20
61. Almyroudis NG, Sutton DA, Fothergill AW, et al. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007;51:2587-90
62. Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother 2006;57:135-8
63. Gonzalez GM. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med Mycol 2009;47:71-6
64. Pfaller MA, Messer SA, Boyken L, et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol 2008;46:2568-72
65. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi. Antimicrob Agents Chemother 2005;49:5136-8
66. Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003;41:3623-6
67. Pfaller MA, Messer SA, Hollis RJ, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002;46:1032-7
68. Perkhofer S, Lechner V, Lass-Flörl C. In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2009;53:1645-7
69. Capilla J, Ortoneda M, Pastor FJ, Guarro J. In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi. Antimicrob Agents Chemother 2001;45:2635-7
70. Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 2001;45:2151-3
71. Gilgado F, Serena C, Cano J, et al. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. Antimicrob Agents Chemother 2006;50:4211-3
72. Ortoneda M, Capilla J, Pastor FJ, et al. In vitro interactions of approved and novel drugs against Paecilomyces spp. Antimicrob Agents Chemother 2004;48:2727-9
73. Meletiadis J, Meis JF, Mouton JW, et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002;46:62-8
74. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005;366:1435-42
75. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36:1122-31
76. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15
77. Cornely OA, Maertens J, Winston DJ, et al. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59
78. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-47
79. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2-12
80. Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006;42:1726-34
81. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006;42:1398-403
82. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006;50:126-33
83. Wingard JR, Carter SL, Walsh TJ, et al. Results of a Randomized, Double-Blind Trial of Fluconazole (FLU) vs. Voriconazole (VORI) for the prevention of Invasive Fungal Infections (IFI) in 600 Allogeneic Blood and Marrow Transplant (BMT) patients. Blood (ASH Annual Meeting Abstracts) 2007;110:163
84. Hata K, Kimura J, Miki H, et al. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1996;40:2243-7
85. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. J Antimicrob Chemother 2002;49:353-7
86. Roberts J, Schock K, Marino S, Andriole VT. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 2000;44:3381-8
87. Beale M, Queiroz-Telles F, Banhegyi D, et al. Randomized, double-blind study of the safety and antifungal activity of ravuconazole relative to fluconazole in esophageal candidiasis. In: abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2001. J-1621. American Society for Microbiology, Washington, DC, USA
88. Warn PA, Mosquera J, Sharp A, et al. In vivo efficacy of the triazole BAL8557 (BAL) compared to voriconazole (VOR), itraconazole (ITC) and caspofungin (CAS) by a new qPCR and quantitative culture in neutropenic murine model of Aspergillus flavus. In: abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract B-48. American Society for Microbiology, Washington, DC, USA
89. Warn PA, Sharp A, Mosquera J, et al. Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. J Antimicrob Chemother 2006;58:1198-207
90. Majithiya J, Sharp A, Parmar A, et al. Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother 2009;63:161-6
91. Viljoen JJ, Mitha I, Heep M, et al. Efficacy, safety, and tolerability of three different dosing regimens of BAL8557 vs fluconazole in a double-blind, randomized, multicenter trial for the treatment of esophageal candidiasis in immunocompromised adults. In: abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract LB2-32. American Society for Microbiology, Washington, DC, USA
92. Bartroli J, Turmo E, Alguero M, et al. New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. J Med Chem 1998;41:1869-82
93. Vericat ML, Algueró M, Merlos M, et al. UR-9825, a novel broad spectrum triazole for treatment of fungal infections: oral activity in systemic mycoses. In: trends in invasive fungal infections, Barcelona, Spain, 1997:P-94
94. Miller JL, Schell WA, Wills EA, et al. In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob Agents Chemother 2004;48:384-7
95. Capilla J, Yustes C, Mayayo E, et al. Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits. Antimicrob Agents Chemother 2003;47:1948-51
96. Bartroli X, Uriach J. A clinical multicenter study comparing efficacy and tolerability between five single oral doses of albaconazole and fluconazole 150 mg single dose in acute vulvovaginal candidiasis. In: abstracts of the Forty-fifth Interscience Conference on Antimicriobial Agents and Chemotherapy, Washington, DC, 2005. Abstract M-722. American Society for Microbiology, Washington, DC, USA
97. Nivoix Y, Levêque D, Herbrecht R, et al. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 2008;47:779-92
98. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005;35:509-13
99. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2997;109:1532-5
100. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46:201-11